Findings

What do systematic reviews say?

4 questions · 5 findings · 3 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 20%Moderate 0 · 0%High 4 · 80%

Major bleeding · Anticoagulants in ACS

Factor Xa inhibitors showed no clear difference in major bleeding at 30 days compared with anticoagulants (high certainty).

2 findings from 1 review

Factor Xa inhibitors for acute coronary syndromes 2011 · Cochrane Headline outcomes only
RR 1.01 [0.98, 1.04]
2 studies · 20404 participants
High
Factor Xa inhibitors for acute coronary syndromes 2011 · Cochrane Headline outcomes only
RR 0.98 [0.92, 1.04]
1 study · 326 participants
High

Major bleeding at 30 days ‐ Enoxaparin · Anticoagulants in ACS

Factor Xa inhibitors leads to higher major bleeding at 30 days ‐ Enoxaparin compared with anticoagulants (high certainty).

1 finding from 1 review

Factor Xa inhibitors for acute coronary syndromes 2011 · Cochrane Headline outcomes only
RR 1.02 [1.01, 1.02]
1 study · 20078 participants
High

Major bleedinge · patients with a pulmonary embolism, confirmed by standard imaging techniques

Oral factor Xa inhibitors showed no clear difference in major bleedinge compared with conventional anticoagulation (low certainty).

1 finding from 1 review

Major bleeding · participants with diagnosed DVT

Oral factor Xa inhibitors leads to lower major bleeding (3 to 12 months) compared with conventional anticoagulation (high certainty).

1 finding from 1 review